Cargando…
Metabolic Profiling during Acute Myeloid Leukemia Progression Using Paired Clinical Bone Marrow Serum Samples
Cellular metabolic changes reflect the characteristics of patients with acute myeloid leukemia (AML) caused by genetic variations, which are important in establishing AML treatment. However, little is known about the metabolic profile of patients with genetic variation-induced AML. Furthermore, the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471543/ https://www.ncbi.nlm.nih.gov/pubmed/34564403 http://dx.doi.org/10.3390/metabo11090586 |
_version_ | 1784574493966991360 |
---|---|
author | Kim, Hyun Kyu Son, Su Young Oh, Jae Sang Song, Ye Na Byun, Ja Min Koh, Youngil Hong, Junshik Yoon, Sung-Soo Lee, Choong Hwan Shin, Dong-Yeop Lee, Man Ryul |
author_facet | Kim, Hyun Kyu Son, Su Young Oh, Jae Sang Song, Ye Na Byun, Ja Min Koh, Youngil Hong, Junshik Yoon, Sung-Soo Lee, Choong Hwan Shin, Dong-Yeop Lee, Man Ryul |
author_sort | Kim, Hyun Kyu |
collection | PubMed |
description | Cellular metabolic changes reflect the characteristics of patients with acute myeloid leukemia (AML) caused by genetic variations, which are important in establishing AML treatment. However, little is known about the metabolic profile of patients with genetic variation-induced AML. Furthermore, the metabolites differ with disease progression. Here, metabolites in the bone marrow serum of ten patients with AML and healthy individuals were analyzed using gas chromatography–mass spectrometry. Compared with that in healthy individuals, expression of most metabolites decreased in patients with AML; hydroxylamine, 2-hydroxybutyric acid, monomethylphosphate, and ethylphosphate expression was unusually increased in the patients. We further examined serial metabolite changes across the initial diagnosis, postremission, and relapse phases. Patients with relapse showed increased metabolite expression compared with those in the diagnostic phase, confirming that patients with AML had aggressively modified leukemic cells. However, a clear difference in metabolite distribution was not observed between the diagnosis and complete remission phases, suggesting that the metabolic microenvironment did not change significantly despite complete remission. Interestingly, metabolite profiles differed with genetic variations in leukemic cells. Our results, which were obtained using paired samples collected during AML progression, provide valuable insights for identifying vulnerable targets in the AML metabolome and developing new treatment strategies. |
format | Online Article Text |
id | pubmed-8471543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84715432021-09-28 Metabolic Profiling during Acute Myeloid Leukemia Progression Using Paired Clinical Bone Marrow Serum Samples Kim, Hyun Kyu Son, Su Young Oh, Jae Sang Song, Ye Na Byun, Ja Min Koh, Youngil Hong, Junshik Yoon, Sung-Soo Lee, Choong Hwan Shin, Dong-Yeop Lee, Man Ryul Metabolites Article Cellular metabolic changes reflect the characteristics of patients with acute myeloid leukemia (AML) caused by genetic variations, which are important in establishing AML treatment. However, little is known about the metabolic profile of patients with genetic variation-induced AML. Furthermore, the metabolites differ with disease progression. Here, metabolites in the bone marrow serum of ten patients with AML and healthy individuals were analyzed using gas chromatography–mass spectrometry. Compared with that in healthy individuals, expression of most metabolites decreased in patients with AML; hydroxylamine, 2-hydroxybutyric acid, monomethylphosphate, and ethylphosphate expression was unusually increased in the patients. We further examined serial metabolite changes across the initial diagnosis, postremission, and relapse phases. Patients with relapse showed increased metabolite expression compared with those in the diagnostic phase, confirming that patients with AML had aggressively modified leukemic cells. However, a clear difference in metabolite distribution was not observed between the diagnosis and complete remission phases, suggesting that the metabolic microenvironment did not change significantly despite complete remission. Interestingly, metabolite profiles differed with genetic variations in leukemic cells. Our results, which were obtained using paired samples collected during AML progression, provide valuable insights for identifying vulnerable targets in the AML metabolome and developing new treatment strategies. MDPI 2021-08-31 /pmc/articles/PMC8471543/ /pubmed/34564403 http://dx.doi.org/10.3390/metabo11090586 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kim, Hyun Kyu Son, Su Young Oh, Jae Sang Song, Ye Na Byun, Ja Min Koh, Youngil Hong, Junshik Yoon, Sung-Soo Lee, Choong Hwan Shin, Dong-Yeop Lee, Man Ryul Metabolic Profiling during Acute Myeloid Leukemia Progression Using Paired Clinical Bone Marrow Serum Samples |
title | Metabolic Profiling during Acute Myeloid Leukemia Progression Using Paired Clinical Bone Marrow Serum Samples |
title_full | Metabolic Profiling during Acute Myeloid Leukemia Progression Using Paired Clinical Bone Marrow Serum Samples |
title_fullStr | Metabolic Profiling during Acute Myeloid Leukemia Progression Using Paired Clinical Bone Marrow Serum Samples |
title_full_unstemmed | Metabolic Profiling during Acute Myeloid Leukemia Progression Using Paired Clinical Bone Marrow Serum Samples |
title_short | Metabolic Profiling during Acute Myeloid Leukemia Progression Using Paired Clinical Bone Marrow Serum Samples |
title_sort | metabolic profiling during acute myeloid leukemia progression using paired clinical bone marrow serum samples |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471543/ https://www.ncbi.nlm.nih.gov/pubmed/34564403 http://dx.doi.org/10.3390/metabo11090586 |
work_keys_str_mv | AT kimhyunkyu metabolicprofilingduringacutemyeloidleukemiaprogressionusingpairedclinicalbonemarrowserumsamples AT sonsuyoung metabolicprofilingduringacutemyeloidleukemiaprogressionusingpairedclinicalbonemarrowserumsamples AT ohjaesang metabolicprofilingduringacutemyeloidleukemiaprogressionusingpairedclinicalbonemarrowserumsamples AT songyena metabolicprofilingduringacutemyeloidleukemiaprogressionusingpairedclinicalbonemarrowserumsamples AT byunjamin metabolicprofilingduringacutemyeloidleukemiaprogressionusingpairedclinicalbonemarrowserumsamples AT kohyoungil metabolicprofilingduringacutemyeloidleukemiaprogressionusingpairedclinicalbonemarrowserumsamples AT hongjunshik metabolicprofilingduringacutemyeloidleukemiaprogressionusingpairedclinicalbonemarrowserumsamples AT yoonsungsoo metabolicprofilingduringacutemyeloidleukemiaprogressionusingpairedclinicalbonemarrowserumsamples AT leechoonghwan metabolicprofilingduringacutemyeloidleukemiaprogressionusingpairedclinicalbonemarrowserumsamples AT shindongyeop metabolicprofilingduringacutemyeloidleukemiaprogressionusingpairedclinicalbonemarrowserumsamples AT leemanryul metabolicprofilingduringacutemyeloidleukemiaprogressionusingpairedclinicalbonemarrowserumsamples |